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Abstract.
OBJECTIVE: This is an analysis of the unpublished continuation phase of Study 329, the primary objective of which was
to compare the efficacy and safety of paroxetine and imipramine with placebo in the treatment of adolescents with unipolar
major depression. The objectives of the continuation phase were to assess safety and relapse rates in the longer term. The
objective of this publication, under the Restoring Invisible and Abandoned Trials (RIAT) initiative, was to see whether access
to and analysis of the previously unpublished dataset from the continuation phase of this randomized controlled trial would
have clinically relevant implications for evidence-based medicine.
METHODS: The study was an eight-week double-blind randomized placebo-controlled trial with a six month continuation
phase. The setting was 12 North American academic psychiatry centres, from 20 April 1994 to 15 February 1998. 275
adolescents with major depression were originally enrolled in Study 329, with 190 completing the eight-week acute phase.
Of these, 119 patients (43%) entered the six-month continuation phase (paroxetine n = 49; imipramine n = 39; placebo n = 31),
in which participants were continued on their current treatment, blinded. As per the protocol, we have looked at rates of
relapse (based on Hamilton Depression Scale scores) across both acute and continuation phases, and generated a safety profile
for paroxetine and imipramine compared with placebo for up to six months.
ANOVA testing (generalized linear model) using a model including effects of site, treatment and site x treatment interaction
was applied. Otherwise we used only descriptive statistics.
RESULTS: Of patients entering the continuation phase, 15 of 49 for paroxetine (31%), 12 of 39 for imipramine (31%) and 12
of 31 for placebo (39%) completed as responders. Across the study, 25 patients on paroxetine relapsed (41% of those showing
an initial response), 15 on imipramine (26%), and 10 on placebo (21%). In the continuation and taper phases combined there
were 211 adverse events in the paroxetine group, 147 on imipramine and 100 on placebo. The taper phase had a higher
proportion of severe adverse events per week of exposure than the acute phase, with the continuation phase having the fewest
events.
CONCLUSIONS: The continuation phase did not offer support for longer-term efficacy of either paroxetine or imipramine.
Relapse and adverse events on both active drugs open up the risks of a prescribing cascade. The previously largely unrecognised
hazards of the taper phase have implications for prescribing practice and need further exploration.
Keywords: Paroxetine, SSRIs, imipramine, depression, relapse, taper phase
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1. Background
In 2013, in response to concerns about selective reporting of outcomes of randomized controlled
trials, an international group of researchers called on funders and investigators of abandoned (unpub-
lished) or misreported trials to publish undisclosed outcomes or correct misleading publications [1].
This initiative was dubbed ‘restoring invisible and abandoned trials’ (RIAT). The researchers identi-
fied many trials requiring restoration, and emailed the appropriate parties, asking them to signal their
intention to publish the unpublished trials or publish corrected versions of misreported trials.
The RIAT researchers approached GlaxoSmithKline (GSK) (formerly SmithKline Beecham: SKB)
and asked whether it intended to restore Study 329, a double-blinded randomized controlled trial
comparing paroxetine and imipramine with placebo in the treatment of adolescent major depression.
GSK did not signal any such intent.
The acute phase of Study 329 was originally reported in the Journal of the American Academy of
Child and Adolescent Psychiatry in 2001 [2]. It was reanalysed and published under the RIAT initiative
in 2015 in BMJ (Le Noury et al.) [3].
The acute phase of Study 329 was followed by a six-month continuation phase. This article represents
a RIAT publication of the continuation phase.
The 1993/1994/1996 trial protocol [4] stated that the objectives for the continuation phase were:
• To provide information on the safety profile of paroxetine and imipramine when these agents are
given to adolescents for an extended period of time;
• To estimate the rate of relapse among paroxetine, imipramine, and placebo responders who were
maintained on treatment (p. 000547).
The clinical study report (CSR) [5] stated that the continuation phase ‘was not designed to determine
whether paroxetine or imipramine are superior to placebo in preventing relapse’, but instead ‘to provide
information on the relapse rates of responders over an extended period’ (p. 000023).
Study enrolment took place between April 1994 and March 1997. The final date on which the last
patient took study medication during the continuation phase was 3 September 1997. In a small number
of patients, 30-day follow-up data were collected into February 1998.
2. Methods
We have reanalysed Study 329 according to the RIAT recommendations. To this end, we have used
the CSR [5], including Appendices A-G (publically available on the GSK website [http://www.gsk.
com/en-gb/media/resource-centre/paroxetine/paroxetine-paediatric-and-adolescent-patients/]), other
publically available documents, [6] and the individual participant level data accessed through SAS Solu-
tions OnDemand website, [7] on which GSK subsequently also posted some Study 329 documents
(available only to users approved by GSK). Following negotiation, [8] GSK posted approximately
77,000 pages of de-identified individual case report forms (CRFs, Appendix H) on that website. A
table of sources of data consulted in preparing each part of this paper is available as RIAT Appendix
1–RIAT Audit Record (RIATAR).
Except where indicated, in accordance with RIAT recommendations, our methods are those set out
in the protocol, [4] as outlined in RIAT Appendix 1.
2.1. Participants
The acute phase participants comprised 275 adolescents between the ages of 12 and 18 years, meet-
ing DSM-IV criteria [9] for a current episode of major depression of at least eight weeks’ duration
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(see Le Noury et al. [3] for details of eligibility criteria, standardization across sites, randomization,
blinding, recruitment, screening, consent, demographic and baseline characteristics). In the continua-
tion phase, patients who had responded to treatment were eligible to continue on the same medication
at the same dosage for an additional six months.
Some participants were not able to progress to the continuation phase because of a shortage of study
medication supplies, resulting from a slower-than-expected rate of enrollment, which led to some of the
medication expiring before use (CSR, p. 000027), Amendment 2 of the Study 329 protocol (approved
28 October 1996) provided two options for these patients: treatment by a third party, who was provided
with the identity of the study medication, or open-label paroxetine treatment for up to six months (after
a one-week down-titration and washout period) by the study physician (p. 000538).
2.2. Interventions
Study medication was provided to patients in weekly blister packs. Patients were instructed to take
the medication twice daily. There were six dosing levels. Over the first four weeks of the acute phase, all
patients were titrated to level 4, corresponding to paroxetine 20 mg or imipramine 200 mg, regardless of
response. Non-responders (those failing to reach responder criteria) could be titrated over the following
four weeks up to level 5 or 6, corresponding to a maximum dose of 60 mg paroxetine 60 mg and 300 mg
imipramine.
Medication compliance was evaluated based on the number of capsules dispensed, taken, and empty
blister packs returned. Non-compliance was defined as taking less than 80% or more than 120% of the
number of capsules expected to be returned at two consecutive visits, and resulted in withdrawal from
the study. Any patient missing two consecutive visits was also withdrawn.
Patients were provided with 45-minute weekly sessions of supportive psychotherapy, [10] primarily
for the purpose of assessing the treatment effects.
2.3. Taper phase
A discontinuation taper phase was recommended for all patients, whether terminating the study
early (during both the acute and continuation phase), or completing the acute phase but not continuing,
or completing the six-month continuation phase. If the patient accepted a taper phase, the protocol
recommended tapering medication/placebo in a linear fashion over a seven to 17 day period, with
patient, family, and clinical and research personnel all remaining blind to medication assignment.
Not all patients agreed to a taper phase. For those who did taper their medication, it was difficult
in some cases to be certain of the exact duration of exposure, because the date of last dose was left
incomplete. We have used the exact number of days where available, and for other patients we have
assumed an average taper phase of 2 weeks, unless there were indications to the contrary. The taper
phase includes patients tapering during the acute phase as well as the continuation phase, so there are
more patients in the taper phase than in the continuation phase.
2.4. Outcomes
Patients were evaluated every four weeks from week 12 to week 32 during the six months of the
continuation phase.
2.4.1. Efficacy Endpoints
a. Percentage of Patients Who Relapsed
The protocol defined patients as relapsed if they no longer met the criteria for response. The protocol
definition of response was having a Hamilton Depression Scale (HAM-D) score ≤ 8, or a 50% or greater
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reduction in HAM-D score relative to the baseline score (such patients were defined as ‘responders’
in the CSR). The CSR added a second indicator of response, ‘remission’, defined as having a HAM-D
score ≤ 8, ‘in order to provide a rigorous anchor point in analyzing relapses in the continuation phase’
(p. 000050). We have accepted this departure from the protocol and applied this more conservative
remission criterion to our analyses of relapses. This reduces the number of relapses.
In addition we have regarded as relapses any patients who, having previously responded, were
discontinued from the study because of a suicide-related event. A number of these patients were
hospitalized or discontinued from the study immediately at that point without a further HAM-D
being completed. We have regarded such cases as relapses even though the most recently undertaken
HAM-D score (prior to the event) might have been < 8. This seems to us a necessary modification of
the protocol as such an outcome was in all likelihood not anticipated when the protocol was developed
or at any point prior to the analysis of the data. The data are available for other researchers to analyse
using other approaches.
b. Percentage of patients withdrawing because of lack of efficacy
The protocol called for the percentage of patients withdrawing because of lack of efficacy to be
evaluated at the end of the continuation phase. We have included in this category those patients whose
final HAM-D scores were consistent with a lack of efficacy, even if the stated reason for withdrawal
was non-compliance or protocol violation or adverse events other than suicide-related events.
2.4.2. Safety endpoints
An adverse experience/event was defined in the protocol (p. 000564) as:
‘any noxious, pathologic or unintended change in anatomical, physiologic or metabolic func-
tions as indicated by physical signs, symptoms and/or laboratory changes occurring in any phase
of the clinical trial whether associated with drug or placebo and whether or not considered drug
related.
This includes an exacerbation of pre-existing conditions or events, intercurrent illnesses, drug
interaction or the significant worsening of the disease under investigation that is not recorded
elsewhere in the case report form under specific efficacy assessments.’
Adverse events were to be elicited by the investigator asking a non-leading question such as: ‘Do you
feel different in any way since starting the new treatment/the last assessment?’ (p. 000565). Details of
treatment-emergent adverse events, including their severity, any change in study drug administration,
investigator attribution to study drug, any corrective therapy given, and outcome status were docu-
mented. Attribution or relationship to study drug was judged by the investigator to be ‘unrelated’,
‘probably unrelated’, ‘possibly related’ or ‘related’ (p. 000565).
2.5. Sources of safety data
Adverse event data come from the CSR of the continuation phase lodged on GSK’s website, primarily
Appendix D: Patient Data Listings of Adverse Experiences. Appendix B provides details of concomi-
tant medications. Additional information was available from the summary narratives in the body of the
CSR for patients who had adverse events that were designated as serious or led to withdrawal. However,
a number of other patients discontinued because of adverse events that were not regarded as serious,
or discontinued because of lack of efficacy or protocol violations, did not generate patient narratives.
The tables in Appendix D of the CSR report the verbatim terms used by the blinded investigators
along with preferred terms as coded by SKB using the Adverse Drug Events Coding System (ADECS)
dictionary. Appendix D also includes ratings of severity and ratings of relatedness. We used the Medical
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Dictionary for Regulatory Activities (MedDRA®) to code the verbatim terms provided in CSR
Appendix D. MedDRA terminology is the international medical terminology developed under the
auspices of the International Conference on Harmonisation of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use (ICH) www.meddra.org). It has been endorsed by the United
States Food and Drug Administration (FDA) and is now used by GSK [11].
Our analysis of the acute phase [3] had established that there are significant adverse event data
missing from CSR Appendix D, so all CRFs for all patients entering the continuation phase were
scrutinised for all adverse events occurring during the continuation phase. These adverse events were
compared with those reported in CSR Appendix D. This review process identified additional adverse
events that had not been recorded as verbatim terms in CSR Appendix D. It also led to recoding of
a number of the reasons for discontinuation. The new adverse events and the reasons for changing
discontinuation category are recorded in RIAT Appendix 2 accompanying this paper.
2.6. Coding of adverse events
The protocol (p. 000574) stated that adverse events were to be coded by body system and preferred
terms, and compared using descriptive statistics, but did not specify a coding dictionary. The CSR
(written after the study concluded) specified that adverse events were coded using the Adverse Drug
Experience Coding System (ADECS), which SKB used at the time (p. 000044). ADECS was derived
from a coding system developed by the FDA, Coding Symbols for a Thesaurus of Adverse Reaction
Terms (COSTART), but ADECS is not itself a recognized system and is no longer available.
We coded adverse events using MedDRA, which has replaced COSTART for the FDA, because it is
by far the most commonly used coding system today. For coding purposes, we have taken the original
terms used by the clinical investigators as transcribed into the CSR Appendix D, and applied MedDRA
codes to these descriptions. Information from Appendix D was transcribed into spreadsheets (available
at Restoring Study329.org). The verbatim terms and the ADECS coding terms were transcribed first
into these sheets, allowing all coding to be done before the drug names were added in. The transcription
was carried out by a research assistant who was a MedDRA trained coder, but took no part in the actual
coding. All coding was carried out by JLN, and checked by DH, or vice versa.
All of our coding from the verbatim terms in the CSR Appendix D was done blind, as was coding
from the CRFs.
In general, MedDRA coding stays closer to the original clinician description of the event than
ADECS. Most coding was straightforward. The vast majority of the verbatim terms simply mapped
onto coding terms in MedDRA. The main coding challenges arose in relation to suicide-related events
in the acute phase; these are covered in Le Noury et al. [3].
2.7. Analysis of safety data
As in our acute study re-analysis, in analysing the safety data, we present all adverse events rather
than only those happening at a particular rate. Secondly, we have grouped events into broader system-
organ-class (SOC) groups–psychiatric, cardiovascular, gastrointestinal, respiratory and other. Thirdly,
we break down events by severity, selecting adverse events coded as severe, and utilising the listing in
the CSR (Appendix G) of patients who discontinued for any reason.
In our acute study re-analysis [3], we laid out our categorization of suicidal events in detail. These
were events whose coding in our opinion should have included a suicide-related code. There were also
a considerable number of events coded under headings such as nightmares or abnormal thoughts. At
the time this study was conceived and executed, few investigators or patients were familiar with the
phenomenon of treatment-induced behavioral change, up to and including suicidality, and no rating
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instruments were included to ensure that such events were recorded systematically. Investigators and
patients were apparently not briefed on this possibility. It is possible that a number of treatment induced
behavioral disturbances would have been communicated obliquely. We have therefore taken events
that might conceal a suicide-related event and presented these together in Table 12a, along with more
clearly suicide-related events. The details of all patients included in this way are laid out in Table 12b.
As the acute and continuation phases are of very different duration, and a significant number of
patients dropped out in the course of the continuation phase, a simple listing of the adverse events from
each phase risks misleading. We have therefore presented the total number of events but also estimated
the rate at which events occurred by duration of exposure.
2.8. Data access
We have made available on Study329.org all the data we have used, with the exception of the actual
CRFs, which we do not have permission to share.
2.9. Statistical methods
No formal hypothesis testing was planned for the continuation phase. We applied ANOVA testing
(generalized linear model) using a model including effects of site, treatment, and site×treatment
interaction as per the Study 329 protocol. Otherwise we used only descriptive statistics.
3. Results
Attrition due to non-response, dropout and relapse is shown in Table 1. Demographic data are laid
out in Table 2. Table 3 has response and relapse data. Tables 4–13 have safety data.
Table 1 shows that only 43 of 275 patients completed the continuation phase.
Table 2 shows the demographic characteristics of those who entered the continuation phase.
Table 1
Allocations and discontinuations in acute and continuation phasesi
Paroxetine N = 93 Imipramine N = 95 Placebo N = 87
SKB RIAT SKB RIAT SKB RIAT
Acute phase dropout 26 26 38 38 21 21
Acute phase completion 67 67 57 57 66 66
Pre-continuation phase dropouts 15 18∗ 17 18∗∗ 33 35#
Continuation phase entry 52 49 40 39 33 31
Continuation phase dropouts 34 31∧ 27 27 20 18
Continuation phase completion 18 18 13 12 13 13
∗Differs from Fig. 1 of Le Noury et al. because during the CRF checks, two additional patients (329.003.00292 and
329.011.00283) were found to have completed the acute phase but never returned for the week 12. They were reclassi-
fied by us as ‘post acute discontinuations’. ∧Patient 329.0002.00058 discontinued during the taper phase of continuation for
AE suicidal overdose. ∗∗Patient 329.008.00161 was originally thought to have entered the continuation phase. However, the
CRF check showed the patient did not return for the week 12 visit, and the notes state that the week 8 medications were
never dispensed. #Again during the CRF check, two placebo patients (329.007.00144 and 329.011.00210) were found to have
completed the acute phase but never returned after their week 8 visit. In addition, for patient 329.005.00334 there was a note
that no study meds were available, so the patient could not continue into the continuation phase. ∼ Patient 329.003.00076 was
originally classed as ‘completed’. However, review of the CRF revealed that the patient stopped study meds approximately
one week prior to the week 32 visit but still attended to complete study paperwork. No down-titration or follow up. This
patient was moved to Discontinuations for protocol violation.
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Table 2
Continuation phase demographics
Paroxetine N = 49 Imipramine N = 39 Placebo N = 31
Mean age (+/–sd) 14.8 (+/–1.7) 14.8 (+/–1.8) 15.0 (+/–1.6)
% female 65% 46% 68%
Caucasian 41 36 25
Black 3 0 1
Hispanic 2 2 2
Other 3 1 3
3.1. Efficacy
The overall profiles of HAM-D scores for observed cases in both acute and continuation phases for
all three arms of the study are presented in Fig. 1.
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Fig. 1. Least Squares Mean ± SEM for the HAM-D scores of the observed cases. The upper eight-week values are from
the remaining acute phase cohort while the lower values are from those selected to enter the continuation phase. ANOVA
testing (generalised linear model) using a model including effects of site, treatment, and site×treatment interaction, as per
the protocol, revealed no statistical significance at any week in either phase.
Although efficacy could be assessed for the acute phase, the dropout rates between the acute and
continuation phases and within the continuation phase were too high to allow a standard efficacy
analysis. In the continuation phase, the dropout rates were 30/49 [61%] for paroxetine; 27/39 [69%]
for imipramine; and 18/31 [58%] for placebo.
Table 3 shows response (remission) and relapse rates, which ranged from 21% for placebo to 41%
for paroxetine. We have included in Table 3 a category of potential completers, to take into account 13
patients who dropped out of the study although their HAM-D scores were well within the responder
range (HAM-D of 2 or 3). Some of them were discontinued because further blinded treatment was
unavailable; for others, no clear explanation for discontinuation was given.
3.2. Discontinuations
During the continuation phase, 75 patients discontinued (30 from paroxetine, 27 from imipramine
and 18 from placebo). The reasons for discontinuation are given in Table 4. Table 4 in RIAT Appendix
2 gives a breakdown of when these dropouts occurred.
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Table 3
Rates of response, relapse and non-response (*)
Paroxetine N = 93 Imipramine N = 95 Placebo N = 87
Response at some point 61 57 47
Completed responders (+ potential completed responders) 15 (+3) 12 (+1) 12 (+9)
Lack of efficacy: acute phase 29 36 38
Lack of efficacy: continuation phase 3 2 2
Acute phase dropouts 9 16 14
Continuation phase dropouts 12 14 11
Acute phase relapse 6 5 3
Continuation phase relapse 19 10 7
Total relapses 25 (41%) 15 (26%) 10 (21%)
∗The term response here uses the more conservative remission criterion defined in the protocol (HAM-D < 8).
Table 4
Reasons for discontinuation during continuation phase
Reason for withdrawal Paroxetine N = 31∗ Imipramine N = 27 Placebo N = 18
SKB RIAT SKB RIAT SKB RIAT
Adverse events 2 5* 8 9 4 4
Lack of efficacy 7 1 6 1 6 2
Relapse 0 4 0 3 0 4
Withdrawn consent 7 9 5 5 2 2
Protocol violation–non-compliance 11 9 6 6 4 3
Protocol violation–by investigator 0 1 0 2 0 0
Lost to follow-up 2 2 1 1 2 3
Other (“Feeling well”) 1 0 0 0 0 0
∗Includes case 58 who discontinued in taper phase of continuation phase.
Following a review of the codes given for reasons for withdrawal from the study that were found
in the CSR (Appendix G), along with a review of patient narratives and CRFs where applicable, we
proposed changes to these reasons for withdrawal in a proportion of those discontinued. These proposed
changes can be found in Table 5 in RIAT Appendix 2.
3.3. Safety
Table 5 gives the number of adverse events reported by SKB in their continuation phase CSR. The
report only provides data on events happening at a 5% or greater rate.
This can be contrasted with the data in Table 6, which presents all adverse events found in both
CSR Appendix D and the CRFs, summarised by System Organ Class (SOC). In MedDRA, some
adverse events always fall within a particular SOC; others require that the coder choose between
SOCs. A full summary and full breakdown of adverse events can be found in Tables 1 and 2 in RIAT
Appendix 2.
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Table 5
Adverse events reported in SKB’s clinical study report (CSR)
Body system Paroxetine N = 52 Imipramine N = 40 Placebo N = 33
Body as a whole 29 14 33
Cardiovascular 1 2 0
Digestive 14 14 25
Psychiatric 0 0 0
Nervous 20 7 6
Respiratory 16 4 9
All other body systems 6 4 6
Total 86 45 79
Table 6
RIAT Summary of all adverse events during continuation phase
Paroxetine N = 49 Imipramine N = 39 Placebo N = 31
System Organ Class (MedDRA) Reported in Further AEs Reported in Further AEs Reported in Further AEs
CSR (App. D) found in CSR (App. D) found in CSR (App. D) found in
only CRF only CRF only CRF
Cardiovascular disorders 18 – 6 1 6 –
Gastrointestinal/digestive disorders 19 3 19 (+2)∗ 3 9 2
Psychiatric disorders 15 9 9 (+1)∗ 11 6 2
Nervous system disorders 35 3 11 3 23 1
Respiratory disorders 20 – 6 – 11 1
All other SOCs 29 1 18 (+1)∗ 1 26 (+1)∗ 2
Total AEs 136 16 69 (+4)∗ 19 81 (+1)∗ 8
Grand total AEs 152 92 90
∗Additional adverse events (AEs) found in patient narratives but missing from CSR Appendix D.
3.4. Severity ratings
Designating adverse events as serious hinged on the judgement of the clinical investigator. We are
therefore not able to make comparable judgements of seriousness, but there are two other methods to
approach the issue of severity of adverse events. One is to look at those rated as severe rather than
moderate or mild at the time of the event (see Table 7).
A full breakdown of the severe adverse events within each SOC can be found in Table 3 of RIAT
Appendix 2. A second method is to look at those that led to dropouts (Table 4).
3.5. Adverse events by exposure
As there were a large number of discontinuations in the continuation phase, a simple listing of
adverse events may tell a different story from an analysis of these events in proportion to the duration
of exposure.
Table 8 shows the weeks of exposure for each group in each phase. Tables 9 and 10 show the
numbers of adverse events and severe adverse events in each phase, with the rates per 100 weeks
exposure displayed in Figs. 2 and 3.
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Table 7
Summary of all adverse events rated as severe during continuation phase
Paroxetine N = 49 Imipramine N = 39 Placebo N = 31
System Organ Class (MedDRA) CSR only (Appendix D) CSR only (Appendix D) CSR only (Appendix D)
Gastrointestinal disorders 1 1 1
Psychiatric disorders 4 3 2
Nervous system disorders 6 2 7
Respiratory disorders – – 3
General disorders – 1 –
All other SOCs 4 1 3
Total severe AEs 15 (9.9%) 8 (8.7%) 16 (17.8%)
Table 8
Total weeks exposure in all phases
Paroxetine Imipramine Placebo
Acute phase (8 weeks) 640 (n = 93) 634 (n = 95) 626 (n = 87)
Continuation phase (six months) 771 (n = 49) 566 (n = 39) 445 (n = 31)
Taper phase (2 weeks) 112 (n = 56) 144 (n = 72) 128 (n = 64)
Table 9
RIAT figures for adverse events in each phase
Paroxetine Imipramine Placebo
Acute phase 457 520 330
Continuation phase 152 92 90
Taper phase 59 55 10
Total AEs 668 667 430
Table 10
RIAT figures for severe adverse events in each phase
Paroxetine Imipramine Placebo
Acute phase 57 41 25
Continuation phase 15 8 16
Taper phase 16 14 1
Total AEs 88 63 42
We have also looked at all behavioral adverse events in each phase (Table 11 and Fig. 4).
These events include: agitation, aggravated depression, akathisia, abnormal dreams, depersonalisation,
disinhibition, feelings of despair, hallucinations, impulsive behavior, negative thoughts, neurosis,
paranoia, psychosis, suicide attempt, suicidal ideation, suicidal gesture, self-harm, and self-injury.
Table 12 gives the numbers of suicidal adverse events in each phase, with the rates per 100 weeks
exposure displayed in Fig. 5. A full listing of all patients who experienced potentially suicidal events
is presented in Table 13.
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Fig. 2. Total adverse events per 100 weeks exposure.
Fig. 3. Severe adverse events per 100 weeks exposure.
3.6. Adverse event profile of patients entering the continuation phase
Patients who completed acute and continuation phases may belong to different cohorts. Accordingly
we analysed the acute-phase adverse event profiles of patients who entered the continuation phase,
compared with those who did not, shown in Table 13. A full breakdown of all these adverse events can
be found in Table 12 in RIAT Appendix 2.
4. Discussion
The original Study 329 investigators are to be commended for undertaking a study that included
a continuation phase for the purposes of providing longitudinal data on the treatment of adolescents
with major depression. As one of the few bodies of data offering information on longer term treatment
of adolescents with mood disorders, the study data are of value.
We analysed and reported the continuation phase according to the original Study 329 protocol (with
approved amendments). RIAT Appendix 1 shows the sources of information used in preparing this
paper, which should aid other researchers who wish to access the data, either to check our analysis or
to interrogate it in other ways. We draw minimal conclusions regarding efficacy and harms, inviting
others to offer their own analysis.
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Table 11
RIAT behavioral events
Paroxetine Imipramine Placebo
TOTAL AEs 74 40 21
Acute phase 49 29 17
Continuation phase 15 10 3∗
Taper phase 10 1 1
TOTAL episodes 53 31 18
Acute phase 34 22 14
Continuation phase 13 8 3
Taper phase 6 1 1
Total no. patients 39 27 16
∗One case either suicidal gesture or trauma.
Fig. 4. Behavioral events per 100 weeks exposure.
Table 12
RIAT suicidality and suicide-related events
Paroxetine Imipramine Placebo
TOTAL AEs 23 11 5
Acute phase 12 6 2
Continuation phase 6 5 3∗
Taper phase 5 0 0
TOTAL episodes 20 9 5
Acute phase 9 4 2
Continuation phase 6 5 3
Taper phase 5 0 0
Total no. patients 15 9 5
∗Includes one case which could potentially be classed as ‘trauma’.
The number of patients relapsing was designated a secondary outcome in Study 329. The results,
however, remain unpublished. In our analysis, although we used more stringent criteria (i.e. remission)
for response, we found higher rates of response in all three treatment groups than were reported in
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Fig. 5. Suicidal adverse events per 100 weeks exposure.
Keller et al. or in the text of the CSRs prepared by SKB, because we followed the classification in the
CSR Appendix D, where response is based on HAM-D scores only, regardless of whether the patient
or investigator violated the protocol.
Our analysis revealed higher relapse numbers in the active treatment groups than in the placebo
group. This is in part determined by our decision to include in the relapse category patients who had a
significant adverse event in the behavioral domain, but the higher numbers hold whether or not these
patients are included.
Relapse was not a primary endpoint of the trial, and cannot be analysed in a way that would allow
a definitive statement about rates of relapse compared to placebo. Furthermore it can be difficult to
distinguish between apparent relapse and an adverse drug reaction, requiring caution in the case of
patients who fail to respond to active treatment. Some of the patients in this study appear to have
become paranoid or manic, or to have had a depressive relapse, all of which might lead to further
diagnoses and/or prescriptions (a prescribing cascade) when in fact the wisest course of action might
be to withdraw treatment.
The data on adverse events controlled for duration of exposure points to the taper phase as the riskiest
period of treatment. It was difficult to be confident of the exact duration of exposure in the taper phase
in some patients, but our estimates of duration are not likely to have inflated adverse event figures.
The CSR argued that simply looking at relapses is not a good way to establish long-term compar-
ative efficacy (p. 000023). It proposed a randomized discontinuation design as the best way forward
(p. 000023). However, the data from this study point to a discontinuation syndrome associated with
paroxetine use. If this is the case, a randomized discontinuation design would not work, and we would
be left with a more naturalistic option like the present study.
With regard to adverse events, the continuation phase of the study stands out as a phase where fewer
adverse events either happened or were recorded. This to some extent is not surprising. It might be
expected that the acute phase would weed out those patients not suited to the treatment they were on.
But simple explanations like this may not fully account for the data, in that the patients entering the
continuation phase appeared to have as many adverse events during the acute phase as those patients
who did not opt to continue with treatment.
There are no other studies in this age group that we are aware of with which this study can be
compared.
In our reporting of the acute phase of Study 329, we suggested that researchers and clinicians
should recognise the potential biases in published research, including the potential barriers to accurate
reporting of harms to which this study pointed. We also urged regulatory authorities to mandate
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Table 13
All potential suicidal events – outline of events per patient
Patient ID No Sex & age Study phase Day of Total AEs within
event onset event
Paroxetine
329.001.00063 F 14 Acute 34 Disinhibition
329.001.00065 M 14 Acute 14 Suicidal ideation
Aggravated depression
Self injury
Feeling of despair
329.001.00205 M 12 Acute 4 Disinhibition
329.002.00055 M 13 Continuation 84 Self harm
Continuation 140 Suicidal ideation
329.002.00058 F 16 Taper during continuation 122 Suicide attempt
329.002.00099 M 15 Continuation 121 Akathisia
329.002.00106 F 15 30 day discontinuation 51 Aggravated depression
Suicidal gesture
329.002.00245 F 14 Acute 14 Suicide attempt
329.003.00075 F 17 Acute 1 Akathisia (teeth chattering)
Akathisia (tremulous)
Acute 51 Akathisia (nervous jittery)
Continuation 170 Akathisia (hyperkinesia)
329.003.00089 F 14 Acute 29 Disinhibition
Acute 56 Suicidal ideation
Agitation
Impulsive behaviour
329.003.00250 F 15 Acute 37 Suicide attempt
Taper during continuation 75 Suicide attempt
329.003.00313 M 18 Acute 12 Suicide attempt
Suicidal ideation
Hallucinations
Psychosis
Psychosis
329.004.00015 F 16 Acute 31 Suicide attempt
Suicidal ideation
Continuation 73 Suicidal ideation
329.004.00017 F 16 Acute 7 Akathisia
Continuation 163 Disinhibition
329.004.00214 F 15 Acute 5 Akathisia
Continuation 84 Suicidal ideation
329.005.00008 M 12 Acute 37 Disinhibition
Continuation 77 Disinhibition
329.005.00011 F 16 Continuation 156 Suicide attempt
329.005.00257 F 12 Continuation 225 Akathisia
329.005.00333 F 16 Acute 19 Abnormal dreams
Aggravated depression
30 day discontinuation 37 Suicidal ideation
329.006.00038 F 15 Acute 57 Suicide attempt
329.006.00039 F 15 Acute 18 Suicide attempt
(Continued)
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Table 13
(Continued)
Patient ID No Sex & age Study phase Day of Total AEs within
event onset event
42 Suicidal ideation
Aggravated depression (more
depressed)
Aggravated depression
(nervousness/irritable mood)
Suicidal ideation
Continuation 84 Aggravated depression
329.007.00145 M 16 Continuation 113 Akathisia
329.007.00268 F 13 Continuation 169 Akathisia
329.007.00309 F 18 Acute 1 Akathisia
329.008.00160 F 14 Acute 20 Akathisia
329.008.00188 F 17 Acute 4 Akathisia
329.008.00271 F 13 Acute 24 Akathisia (feelings of shakiness/
tremor)
Acute 63 Akathisia (increased
irritability/nervousness)
Continuation 65 Akathisia (shaky/tremor)
329.009.00130 M 15 Acute 32 Akathisia
329.009.00170 F 14 Continuation 237 Negative thoughts
Suicidal ideation
Agitation
Akathisia
329.009.00173 F 12 Acute 40 Akathisia
329.009.00193 F 12 Acute 4 Akathisia
329.009.00201 M 14 Acute 58 Akathisia
Paranoia
329.009.00240 M 14 Acute 48 Aggravated depression
329.009.00324 F 13 Acute 15 Abnormal dreams (nightmares)
29 Abnormal dreams (increased dreaming)
329.009.00329 M 14 Acute 35 Aggravated depression
329.010.00278 F 17 Acute 24 Akathisia
329.011.00283 M 17 Acute 27 Akathisia
329.011.00288 M 15 Acute 48 Agitation (also AE of mutism at same
time. Patient sent to psychiatric unit
and removed from study)
329.012.00025 F 14 Acute 1 Akathisia
Imipramine
329.001.00070 M 12 Acute 7 Akathisia
329.002.00057 F 15 Acute 20 Akathisia
329.002.00100 M 15 Continuation 84 Self harm
329.002.00103 F 14 Continuation 224 Suicidal ideation
Aggravated depression
329.002.00243 F 15 Acute 9 Akathisia
329.002.00244 F 17 Acute 3 Depersonalisation
(Continued)
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Table 13
(Continued)
Patient ID No Sex & age Study phase Day of Total AEs within
event onset event
329.003.00247 M 16 Acute 45 Akathisia
329.004.00215 F 14 Acute 37 Akathisia
Abnormal dreams
Hallucinations
329.005.00003 F 13 Acute 8 Akathisia
329.005.00006 M 17 Continuation 84 Suicidal ideation
Continuation 116 neurosis
329.005.00007 F 15 Continuation 145 Abnormal dreams
329.005.00113 F 15 Acute 32 Suicidal gesture
Suicidal ideation
(pt taken to ER)
329.005.00117 F 16 Acute 29 Akathisia
329.005.00255 F 15 Acute 2 Akathisia (shakiness)
Acute 33 Akathisia (hand tremors)
329.005.00295 F 13 Acute 23 Suicide attempt
329.006.00040 F 18 Acute 7 Aggravated depression
329.006.00041 M 18 Acute 12 Aggravated depression
329.007.00146 F 15 Continuation 172 Akathisia
329.008.00161 M 17 Acute 1 Akathisia
329.009.00172 F 13 Acute 36 Abnormal dreams
Agitation
329.009.00194 M 12 Acute 3 Abnormal dreams (increased dreaming)
Abnormal dreams (nightmares)
329.009.00264 F 14 Acute 11 Akathisia
329.009.00325 F 15 Acute 35 Abnormal dreams
Continuation 112 Aggravated depression
Self harm
329.009.00326 M 13 30 day discontinuation 26 Akathisia
329.010.00279 F 13 Acute phase 33 Suicidal ideation
329.012.00221 M 17 Acute 30 Disinhibition
Continuation 132 Suicide attempt
329.012.00223 F 13 Acute 26 Suicidal ideation
Suicide attempt
Aggravated depression
Placebo
329.001.00123 F 16 Acute 46 Suicidal ideation
Aggravated depression
329.002.00241 M 15 Continuation 108 Suicidal ideation
329.003.00252 F 14 Acute 37 Akathisia
329.005.00120 M 13 Acute 21 Akathisia (nervousness) dy21
Akathisia (nervousness) dy23
Disinhibition (laughing a lot/euphoria)
dy21
(Continued)
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Table 13
(Continued)
Patient ID No Sex & age Study phase Day of Total AEs within
event onset event
329.005.00331 F 15 Acute 3 Akathisia
Acute 18 Depersonalisation
329.007.00266 F 12 Acute 5 Akathisia
329.008.00158 F 16 Continuation 112 Suicidal ideation
329.008.00191 F 17 Acute 28 Akathisia
329.009.00129 M 16 Acute 35 Suicidal ideation
329.009.00135 F 17 Acute 42 Aggravated depression
329.009.00169 M 13 Acute 64 Disinhibition
329.009.00197 M 12 Continuation 172 Suicide attempt (or trauma)
329.009.00198 F 17 Acute 2 Abnormal dreams
Acute 15 Akathisia
329.009.00238 F 16 Acute 15 Abnormal dreams
329.012.00027 M 15 Acute 16 Akathisia
329.012.00217 F 14 30 day discontinuation 30 Aggravated depression
Table 14
Total (and severe) adverse events occurring during the acute phase for acute phase only patients versus continuing patients
Paroxetine Imipramine Placebo
System Organ Class (MedDRA) Acute phase Continuing Acute phase Continuing Acute phase Continuing
only patients patients only patients patients only patients patients
n = 44 n = 49 n = 56 n = 39 n = 56 n = 31
Cardiac and vascular disorders 14 (1) 26 91 (3) 36 22 10
Gastrointestinal disorders 45 (5) 62 (16) 74 (9) 59 (7) 45 (2) 32 (2)
Psychiatric disorders 58 (18) 42 (6) 39 (4) 24 20 (4) 7 (1)
Nervous system disorders 31 (1) 63 (5) 73 (9) 34 (3) 55 (3) 22 (4)
Respiratory and thoracic disorders 18 (1) 21 (1) 15 (1) 7 27 (2) 13 (2)
All other SOCs 24 53 (3) 44 (4) 24 (1) 51 (1) 26 (4)
Total AEs 190 (26) 267 (31) 336 (30) 184 (11) 220 (12) 110 (13)
access to trial data. This analysis of the continuation phase of Study 329 adds further weight to this
recommendation.
It also adds weight to our invitation to others to access the data we have used. We are very clear that
the analyses offered here are not the only ones possible. Our understanding of this dataset can only be
enhanced by input from others who may make differing calls regarding coding and/or apply different
analytic tools to the data.
Trial Registration
Registration number and name of trial register: SmithKline Beecham study 29060/329.
Trial Protocol
SmithKline Beecham study 29060/329, Final Clinical Report (Acute Phase) [5], Appendix A,
Protocol (from p. 000531) [4].
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IRB that approved the study.
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